Medication Administration Guidelines

Introduction to Medication Administration

• The American Academy of Family Physicians and American Heart Association provide guidelines for medication management in patients with anxiety and depression, considering factors such as chronic kidney disease (CKD) 1, 2

Dosage and Efficacy

• For patients with mild to moderate agitation, an initial dosage of 5mg twice daily is recommended, with a maximum dosage of 20mg three times daily, and a delayed onset of action of 2-4 weeks, making it unsuitable for acute anxiety, as noted by the American Academy of Family Physicians 2
• Sertraline is recommended as a first-line treatment for anxiety and depression, starting with a lower dose of 25 mg daily, due to its lower risk of QTc prolongation compared to other SSRIs, as suggested by the American Heart Association and Kidney International guideline 1, 3
• Mirtazapine can be beneficial for chronic anxiety, particularly if insomnia or poor appetite is present, at a starting dose of 7.5 mg at bedtime, with a maximum dose of 15-30 mg at bedtime, as recommended by the American Academy of Family Physicians 1, 2
• Diazepam can be used for acute or situational anxiety at a dose of 0.1-0.8 mg/kg as a single oral dose, with no dose adjustment required in renal failure, as suggested by the American College of Cardiology 4

Medication Considerations in CKD Patients

• The following medications have specific considerations in CKD patients:

3, 1, 2, 4

• Tricyclic antidepressants and MAOIs should be avoided due to significant cardiovascular side effects, and caution should be exercised with certain medications, including fluoxetine and paroxetine, due to their potential for drug accumulation and anticholinergic effects, as recommended by the American College of Cardiology and Kidney International guideline 3, 1, 2
• Duloxetine accumulation is expected with multiple dosing in advanced CKD, and its use is not recommended in patients with severe renal impairment (GFR <30 ml/min), as suggested by the Kidney International guideline 3

Non-Pharmacological Approaches

• Cognitive behavioral therapy, regular aerobic exercise, and mindfulness practices have demonstrated efficacy in reducing depression in dialysis patients, and may be equally effective with fewer side effects compared to pharmacological approaches, as recommended by the Kidney International guideline 3
• Non-pharmacological approaches are preferred due to their lower risk of side effects and potential equal effectiveness, as noted by the Kidney International guideline 3

Dosing Considerations in CKD

• In CKD Stage 3-4, start with 50% of the normal dose for SSRIs, and in CKD Stage 5/Dialysis, prefer benzodiazepines that don't require dose adjustment, following the principles of "start low, go slow" 4, 1, 3
• Gradually uptitrate from subtherapeutic doses while monitoring for efficacy and safety, checking for adverse effects more frequently than in patients with normal kidney function, and be aware of potential interactions, such as between glipizide and fluoxetine 1, 5, 3

Monitoring and Adjustments

• Monitor closely for side effects, as they occur more frequently in CKD patients, and be aware that depression is common in CKD (14-30% prevalence) and associated with increased mortality, as noted by the Kidney International guideline 3
• Consider that as GFR decreases further, medication adjustments may be needed, and recognize that non-pharmacological approaches may be equally effective with fewer side effects, as suggested by the Kidney International guideline 3